ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
24 hedge funds and large institutions have $14.8M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
14% more funds holding
Funds holding: 21 → 24 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.43% less ownership
Funds ownership: 38.28% → 34.85% (-3.4%)
19% less capital invested
Capital invested by funds: $18.3M → $14.8M (-$3.47M)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$230K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$216K |
| 3 |
Jane Street
New York
|
+$189K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$47.6K |
| 5 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$45.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.5M |
| 2 |
FTUS
Flow Traders U.S.
New York
|
-$755K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$477K |
| 4 |
Citigroup
New York
|
-$107K |
| 5 |
LPL Financial
San Diego,
California
|
-$70.1K |
CNCR Hedge Fund Activity: Q3 2021 in Review
24 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2021, worth a combined $14.8M — down 19% from $18.3M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CNCR positions and 1 closed out — a net gain of 4 holders — while 3 added to existing stakes and 8 trimmed.
The largest buyer was BCWM LLC, adding an estimated $230K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.5M sold.
- 24 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2021, up from 21 in Q2 2021.
- Funds reported $14.8M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2021, down 19% quarter-over-quarter.
- 5 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2021 and 1 closed out, a net change of +4 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q3 2021 was BCWM LLC, an estimated $230K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2021 was Citadel Advisors, an estimated $1.5M sold.
Based on aggregated 13F filings for Q3 2021.